News Corporation Class A Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? News Corporation Class A Common Stock trades at $29.12 (market cap $16.14B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: News Corporation Class A Common Stock is the larger of the two by market cap, and News Corporation Class A Common Stock pays a 0.69% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold News Corporation Class A Common Stock for 1 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NWSA | XBI | |
|---|---|---|
Market Cap | $16.14B | $10.11B |
Volume | 4,310,610 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $31.19 | $169.55 |
52-Week Low | $22.40 | $104.99 |
Typical Hold Time | 1 Days | 38 Days |
Enterprise Value | $16.96B | — |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Trailing returns across standard periods
News Corporation operates businesses in news and information services, digital real estate, and book publishing. Its brands include Dow Jones, The Wall Street Journal, HarperCollins, Realtor.com, and realestate.com.au.
Read more on NWSA →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →